Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingApr 17, 2019LOSARTAN POTASSIUM TABLETSCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1115-2019Class IIOngoingApr 17, 2019LOSARTAN POTASSIUM TABLETSCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1114-2019Class IITerminatedApr 17, 2019Gavilyte-NLabeling Not Elsewhere Classified; orange and cherry flavor packets incorrect list "natural lemon flavor" as an ingredientLupin Somerset · D-1113-2019Class IITerminatedApr 17, 2019Life-Line tm Catalytic Activated Energy WaterUnapproved new drugMcDaniel Life-Line LLC · D-1112-2019Class IITerminatedApr 17, 2019Indian Herb PasteUnapproved new drugMcDaniel Life-Line LLC · D-1111-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 17.44-0.64MG-5.8MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1110-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 17.44-0.58MG-5.8MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1109-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 15-0.25MG-6MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1108-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 30-1 MG-20 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1107-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 9-1 MG-10 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1106-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 22.5-0.8MG-8.3MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1105-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 17.64-0.58MG-5.88MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1104-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 16.6-0.55 MG-11.1 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1103-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 15-0.5MG-10MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1102-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 30-2 MG-30 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1101-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE 30-0.5 MG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1100-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE 15-0.5MGMG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1099-2019Class IITerminatedApr 17, 2019PGE1-LIDOCAINE 40 MCG-1% /ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1098-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 30-1.6 MG-16 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1097-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 23-0.96MG-19.2MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1096-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 17.16-0.57MG-19.45MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1095-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 12-1MG-10MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1094-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 30-1 MG-10 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1093-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE 30-1 MG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1092-2019Class IITerminatedApr 17, 2019PGE1 40 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1091-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 22-0.8 MG-8 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1090-2019Class IITerminatedApr 17, 2019HYDROXYPROGESTERONE CAPROATE 250 MG/ML OIL* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1089-2019Class IITerminatedApr 17, 2019ACETYL-L-CYSTEINE 10% P.F. OPHTH SOLUTIONLack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1088-2019Class IITerminatedApr 17, 2019DEXAMETHASONELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1087-2019Class IITerminatedApr 17, 2019SODIUM CHLORIDE PRES-FREE 5% OPHTH STERILE* SOLUTION. 20ml eye dropsLack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1086-2019Class IIITerminatedApr 17, 2019Clonidine HCL InjectionLabeling: Label Error on Declared Strength: Side carton panel incorrectly lists the concentration as "500 mcg Clonidine Hydrochloride" rather than the correct...X-Gen Pharmaceuticals Inc. · D-1084-2019Class IITerminatedApr 17, 2019Losartan Potassium 100 mg Tablets # 30 Losartan potassium tablets USPCGMP Deviations:Traces amounts of N-Nitroso N-Methyl 4- amino butyric acid (NMBA) impurity found in Active Pharmaceutical Ingredient (API).H J Harkins Company Inc dba Pharma Pac · D-1083-2019Class IIITerminatedApr 17, 2019Biotin 10 mg/mL InjectionFailed pH Specification: product does not meet pH label claim.Auro Pharmacies Inc. DBA Central Drugs · D-1082-2019Class IITerminatedApr 17, 2019Losartan 50mg TabletCGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).RemedyRepack Inc. · D-1081-2019Class IIITerminatedApr 10, 2019Nystatin Oral SuspensionFailed Impurities/Degradation Specifications: Out of Specification for an unknown impurity was observed during the 18 month stability testing.Akorn, Inc. · D-1080-2019Class IITerminatedApr 10, 2019NORepinephrine 4 mg added to 5% Dextrose 250 mL BagLabeling: Label mix-upKRS Global Biotechnology, Inc · D-1079-2019Class IITerminatedApr 10, 2019NORepinephrine 16 mg added to 0.9% Sodium ChlorideLabeling: Label mix-upKRS Global Biotechnology, Inc · D-1078-2019Class IITerminatedApr 10, 2019Morphine Sulfate USP MilledMicrobial Contamination of Non-Sterile Products: Bioburden out of specification results for Morphine Sulfate API.Johnson Matthey Inc. · D-1077-2019Class IITerminatedApr 10, 2019Cefuroxime 10mg/mL INJ 0.5 mgPresence of Particulate Matter: Particulate matter was reported in one lot of Cefuroxime by a physician after use of product.. FDA analysis identified the particulate as...Pacific Compounding Pharmacy & Consultations Inc · D-1076-2019Class IITerminatedApr 10, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.Legacy Pharmaceutical Packaging LLC · D-1075-2019

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.